A phase 2 trial assessed a combined respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine in adults aged 60–85 years in the USA. 264 participants received a single dose of either the unadjuvanted vaccine (n=102), the vaccine plus an oil-in-water adjuvant (n=109), or placebo (n=53). Within 7 days, 66·4% of vaccinated participants versus 37·7% of placebo recipients reported at least one solicited adverse reaction, all of which were mild to moderate in severity. Tenderness was the most common injection-site reaction, reported in 40·8% of the unadjuvanted vaccine group, 56·5% of the adjuvanted vaccine group, and 7·5% of the placebo group.
Source link